Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > Will Pfizer & Revive work to develop and commercialize Buc ?
View:
Post by cool888 on Dec 28, 2020 1:05pm

Will Pfizer & Revive work to develop and commercialize Buc ?

Just a thought..... anything is possible..... comments are always appreciated !!!
Myovant Shares Surge on Collaboration With Pfizer

Shares of Myovant Sciences Ltd. rose more than 30% on Monday after the biopharmaceutical company inked a collaboration potentially worth more than $4 billion with Pfizer Inc.

Under the deal, the companies will work to develop and commercialize Myovant's relugolix in oncology and women's health in the U.S. and Canada.

Myovant said it will receive an upfront payment of $650 million, along with potential regulatory and sales milestones, for a total payment of up to $4.2 billion.

Myovant earlier this year received U.S. Food and Drug Administration approval of relugolix, to be marketed as Orgovyx, for the treatment of adults with advanced prostate cancer.

The agency is currently reviewing a relugolix combination tablet for women with uterine fibroids, with a target action date of June 1, 2021. Myovant also is developing the combination tablet for women with endometriosis.

Myovant shares were recently up 30.3% to $29.65.

Comment by SmartPodhotzone on Dec 28, 2020 6:33pm
More like vaccines from majors will Take this pump and dump to zero
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities